The Indonesian Government Strives to Build a National Plasma-Derived Medicinal Ecosystem
The Indonesian government is currently working to build a self-sufficient ecosystem for plasma-derived medicines within the country. This step is being taken to address accessibility challenges, which have long been a major obstacle for the Indonesian people in obtaining these medicinal products.
Plasma-derived medicines are medical products derived from human blood plasma. These products are crucial for treating various critical illnesses, such as immune system disorders, severe burns, and blood clotting diseases. Currently, the demand for these products is still heavily dependent on imports from abroad.
Dependence on imports causes drug prices to be expensive and their availability is often uncertain. By building a national ecosystem, the government hopes to increase Indonesia's pharmaceutical independence. This also aims to ensure that the distribution of medicine to hospitals in every corner of the country becomes faster and more affordable.
Beyond the economic aspect, the development of a domestic plasma industry is also considered capable of improving the quality of national healthcare services. Through collaboration between health agencies and the industrial sector, Indonesia aims to have a plasma processing system that meets international standards.
Overall, this initiative is a strategic step to strengthen national health resilience. If successful, Indonesia will not only reduce its dependence on foreign products but will also be able to provide better health protection for the entire community.